BRD2 and obesity disorder: Currently, carbon-11-labeled methylreboxetine ([11C]MRB) is the clinically most applied radiotracer to visualize and quantify NAT availability in vivo in order to assess whether changes of NA/NAT are associated with excessive weight gain and obesity.